|Bid||20.37 x 1300|
|Ask||20.50 x 900|
|Day's Range||20.31 - 20.85|
|52 Week Range||20.31 - 58.72|
|Beta (5Y Monthly)||0.82|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 05, 2021 - May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.44|
SAN FRANCISCO / ACCESSWIRE / April 9, 2021 / Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the investigations, including important upcoming deadlines, can be found at the links provided.
NEW YORK, NY / ACCESSWIRE / April 9, 2021 / Labaton Sucharow LLP a national securities litigation firm, announces that it is investigating Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) for potential violations of the federal securities laws.
San Francisco, California--(Newsfile Corp. - April 8, 2021) - Hagens Berman invites Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims.Visit: www.hbsslaw.com/investor-fraud/ACADContact An Attorney Now: ACAD@hbsslaw.com844-916-0895Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Investigation:The investigation focuses on the accuracy of Acadia's disclosures concerning its supplemental new drug application ("sNDA") for NUPLAZID® (pimavanserin) for the treatment ...